Oncology Drug Reference Sheet: Lutetium Lu 177 Dotatate

Lutetium Lu 177 dotatate (Lutathera^®) was approved in January 2018 by the U.S. Food and Drug Administration (FDA) to treat a specific group of neuroendocrine tumors (NETs) in the gastrointestinal tract. NETs are rare, and the tumors produce hormone-like substances in response to signals from the nervous system.